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Abstract
Background—Idiosyncratic drug induced liver injury (DILI) is a rare but potentially serious 
liver disorder and a major cause of significant liver injury. Limited data exist on racial differences 
in DILI incidence, presentation and course.
Aim & Methods—We compared the causative agents, clinical features and outcomes of DILI 
among self-described African-Americans and non-Hispanic whites (Caucasians) enrolled in the 
DILIN Prospective Study. Individuals with definite, highly likely, or probable DILI enrolled 
between Sept 2004 and Feb 2016 were included in this analysis.
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Results—144 African-Americans and 841 Caucasian patients met the eligibility criteria. Causal 
medications varied by race: trimethoprim/sulfamethoxazole being the most common cause among 
African-Americans (7.6% vs 3.6%) followed by methyldopa (4% vs <1%), phenytoin (5% vs 
<1%), isoniazid (4% vs 4%) and amoxicillin/clavulanate (4.1% vs 13.4%). The severity of illness, 
however, tended to be greater in African-Americans than Caucasians as determined by peak mean 
bilirubin (14.3 vs 12.8 mg/dL), INR (1.9 vs 1.6) and DILIN severity score (3.0 vs 2.6). The 
frequency of severe cutaneous reactions was significantly higher in African-Americans (2.1 vs. 
0.36% in Caucasians, p=0.048). African-Americans also had higher rates of hospitalization 
(76.7% vs 57.6%, p<0.001), liver transplantation or liver related death by 6 months (10.2% vs 
5.8%, p=0.02 after controlling for selected covariates) and chronic DILI (24% vs. 16%, p=0.06).
Conclusions—The most common DILI causative agents differ between African-Americans and 
Caucasians. African-Americans are more likely to have severe cutaneous reactions and more 
severe liver injury leading to worse outcomes, including death and liver transplant. [Word Count 
250]
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Introduction
Idiosyncratic drug induced liver injury is a rare but clinically important entity with a recent 
population frequency of 15 events per 100,000 inhabitants in the Western world (1). The 
prompt discontinuation of the implicated agent improves the liver injury event in the 
majority suffering from DILI, but there is a high rate of hospitalization and rarely, acute liver 
failure leading to liver transplantation or death (2,3). Furthermore, recent reports suggest that 
sizable number of acute DILI events may lead to chronic liver disease with demonstrable 
long-term histological damage. A recent report from the DILIN observed that severe 
cutaneous reactions accompanied one percent of DILI events and were associated with high 
mortality rate (2).
Established in 2003, the United States Drug-Induced Liver Injury Network (DILIN) is 
conducting a prospective study of individuals who are ≥2 years of age with suspected DILI 
at several clinical centers across the United States (5). Individuals enrolled into this study are 
from varying ethnic and racial backgrounds and the DILIN Prospective Study has enrolled 
over 100 individuals who are of self-reported African-American race. This diversity 
provides an opportunity to characterize the causative agents and the characteristics and 
outcomes of DILI in this important demographic. During the conduct of this study, we 
anecdotally observed some differences in terms of causative agents or skin reactions among 
various racial and ethnic groups. There is a suggestion in the literature that certain adverse 
drug reactions (ADRs) have different frequency and clinical phenotypes in different racial 
and ethnic groups. For example, it was recently observed that African-Americans are at 
significantly higher risk for allopurinol-induced Stevens-Johnson syndrome, an ADR which 
shares overlapping features with DILI (6). In a report from the United States Acute Liver 
Failure Study Group (ALFSG), Forde et al. have shown that blacks (24.4%) were more 
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likely to have acute liver failure due to drugs than whites (14.9%, p=0.015) (7). Recent 
studies have also highlighted racial and ethnic differences in the prevalence and 
characteristics of nonalcoholic fatty liver disease (8,9). This prompted us to carefully 
analyze DILI in self-reported African-Americans enrolled in the DILIN Prospective Study. 
The objectives of this report are to compare the profile of causative agents, the clinical 
characteristics and the outcomes of DILI in African Americans in comparison to Caucasians.
Methods
The DILIN Prospective Study (NCT 00345930) is conducted by the United States Drug 
Induced Liver Injury Network which is funded as a cooperative agreement by the National 
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes 
of Health. DILIN consists of 6 to 8 medical centers, a central data coordinating center and a 
sample repository. The DILI Prospective Study design, method of causality assessment and 
various scoring systems have been described in detail elsewhere (5). The study was approved 
by the appropriately convened institutional review boards at the participating clinical centers 
and data coordinating center as well as by a Data Safety and Monitoring Board appointed for 
this purpose by the NIDDK. All participants provided written informed consent before 
enrollment. The DILIN Prospective Study has been the source for multiple publications on 
topics which ranged from overall patient population characteristics to phenotypes and sub-
phenotypes and select implicated agents (10–17). Participants who form the basis for this 
report were included in other reports published by the DILIN. All participants completed a 
questionnaire that captured self-reported racial and ethnic information. Cases of DILI that 
underwent formal causality assessment and were judged to be definite, highly likely, or 
probable were eligible for inclusion in this analysis.
Data Management and Analyses
Demographic and clinical data for subjects enrolled into the DILIN Prospective Study 
between September 2004 and February 2016 were extracted on February 12, 2016. 
Descriptive statistics, such as means with SD, median with interquartile ranges and 
frequency distributions were used to describe the cohort. Between group difference were 
tested using the χ2 test for categorical variables and Wilcoxon/Kruskal-Wallis test for the 
continuous variables. In the logistic regression analyses, the relationship between African-
American race and DILIN Severity Score and patient outcomes (liver transplant/death or 
chronic DILI) was adjusted for age, body mass index, and diabetes. Statistical analyses were 
performed using SAS software, version 9.2 (SAS Institute, Inc, Cary, NC) and P value <.05 
was considered statistically significant.
Results
Between September 2014 and February 2016, 1620 individuals were enrolled into the 
DILIN Prospective Study and 1455 had undergone six months of follow up and formal 
causality assessment of whom 1182 were scored as definite, highly likely, or probable. 
These confirmed DILI cases included 144 individuals who self-reported their ethnicity and 
race as non-Hispanic Black or African-American and 841 who reported being non-Hispanic 
Whites or Caucasians. The remaining 191, reported their ethnicity and race as Asian (n=41), 
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Hispanic (n=86) or other (n=36) or did not provide ethnic and racial information (n=6). The 
construction of the patient cohort for analysis is shown diagrammatically in Figure 1. The 
analysis was limited to cases occurring among non-Hispanic whites (Caucasians) and blacks 
(African Americans).
A comparison of the demographic, clinical and biochemical features of the two study groups 
are shown in Table 1. In comparison to Caucasians, African-Americans with DILI tended to 
be younger with significantly higher BMI and higher prevalence of diabetes but lower 
frequency of prior drug allergies or alcohol consumption history. Gender and the frequency 
of preexisting liver disease were not different between two groups. There were more African 
Americans with DILI who lacked any health insurance or were without at least a high school 
education.
The five leading therapeutic classes and top 10 single prescription agents implicated among 
the 144 African-Americans and 841 Caucasians are shown in Table 2. In general, there were 
no significant differences in the classes of agents implicated between two groups, with 
antimicrobials, herbal and dietary supplements, cardiovascular system agents, and central 
nervous system agents being the most commonly implicated classes. However, there 
appeared important differences in the individual agents that were implicated in causing DILI 
between the African-American and Caucasian groups(Table 2). The combination of 
trimethoprim and sulfamethoxazole (TMP/SMZ) was the most common agent implicated in 
causing DILI in African-Americans (7.6%) and its frequency was significantly higher than 
in Caucasians (3.6%, p=0.04). In contrast, the combination of clavulanic acid with 
amoxicillin (Clav/Amox) was the most commonly implicated agent in DILI among 
Caucasians (13.4%), but it ranked fourth and its frequency was significantly lower among 
African-Americans (4.1%, p<0.001). Additionally, compared to Caucasians, African-
Americans had significantly higher frequency of liver injury due to phenytoin (4.8% vs. 
0.8%, p=0.002), methyldopa (4.1% vs. 0.5%, p=0.001), and allopurinol (2.7% vs. 0.4%, 
p=0.01). These 3 agents ranked 3rd, 5th and 8th among African Americans but only 24th, 41th 
and 51th among Caucasians.
The time between initiating the implicated medication or herbal agent and onset of DILI 
(latency) and the interval between earliest symptoms of liver injury and discontinuation of 
the suspected medication (delay in stopping) were not different between the African-
Americans and Caucasian groups. In addition, the degrees of likelihood as assessed by 
RUCAM, DILIN causality scores and DILIN causality categories were similar between the 
two groups (Table 3). The R-ratio or the patterns of liver injury at presentation were 
minimally different between the two groups, although there was a trend towards the “mixed 
hepatocellular-cholestatic” pattern of liver injury being less frequent among African-
Americans with DILI than Caucasians (17% vs 24%, p=0.078). While the degree of 
elevation of serum enzymes at onset of DILI was not different between the two groups, peak 
levels of ALT and INR were significantly higher in African Americans than in Caucasians, 
and the peak total bilirubin was higher but these differences were not statistically significant. 
The time to improvement in serum liver biochemical tests was similar in the two racial 
groups.
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Assessment of severity using the DILIN scoring system indicated that the liver injury was on 
average more severe among African-Americans than Caucasians (Table 3). Thus, the mean 
DILIN severity scores were significantly higher in African-Americans than Caucasians (3.0 
vs 2.6), and the distribution of scores was skewed to a higher frequency of severe and fatal 
cases among African-Americans compared to Caucasians (34% vs 24%). Among age, BMI, 
and diabetes, only BMI had statistically significant univariate relationship with the DILIN 
severity score. When we controlled for BMI, the relationship between African-American and 
DILIN severity score statistically significant (OR 1.98, 95% CI: 1.42–2.75, p<0.001). The 
frequency of severe liver injury leading to death or requiring liver transplantation was higher 
in African-Americans (10.2%) than in Caucasians (5.8%). Among age, BMI, and diabetes, 
both age and BMI had statistically significant univariate relationship with the DILIN 
severity score. When we controlled for age and BMI, the relationship between African-
American and the likelihood of death or liver transplantation statistically significant (OR 
2.12, 95% CI: 1.12–3.9, p=0.02).
In addition, chronicity was more frequent in the DILIN cases among African-Americans 
than Caucasians (24% vs. 16%), but this difference was of borderline statistical significance 
(p=0.06). Finally, severe cutaneous reactions occurred in 0.6% of patients in this cohort and 
were more frequent in African-Americans than Caucasians (2.1 vs. 0.36%, p=0.048). Two of 
the cases with severe cutaneous reactions were attributed to lamotrigine (n=2) and one each 
to carbamazepine, azithromycin, and nitrofurantoin.
There were no significant differences in the latency, liver biochemical tests at presentation or 
their peak values, R-ratio, or outcomes (such as death or liver failure needing liver 
transplantation) of liver injury caused by TMP/SMX, amoxicillin-clavulanate, isoniazid, 
nitrofurantoin, or phenytoin between African-Americans and Caucasians. While the severity 
of liver injury due to TMP/SMX, amoxicillin-clavulanate, isoniazid, or nitrofurantoin was 
not different between African-Americans and Caucasians, there were significantly higher 
number of severe/fatal liver injury events due to phenytoin in African-Americans than in 
Caucasians (86% vs. 14%, p=0.008).
Discussion
Our study adds to a growing body of literature showing racial and ethnic differences in the 
frequency and nature of adverse drug reactions (ADRs). A recent systematic review found 
no consistent relationship between race and ADRs in general but noted that certain racial 
groups may be at higher risk for ADRs due to certain classes of agents (18). Asians were 
found to be higher risk for ADRs from oral anticoagulants whereas blacks were at higher 
risks from antidiabetic agents and whites from opiate analgesics (18). In a study of United 
States Vital Statistics, deaths due to ADRs were significantly more frequent in African-
Americans than Caucasians, Hispanics, or Asians (19). Asians and blacks appear to be at 
significantly higher risk for severe cutaneous reactions due to allopurinol and this 
phenomenon is strongly associated with higher frequency of HLA-B*5801 in Asians and 
blacks (6). A few studies investigated the relationship between race and ethnicity and 
hepatotoxicity from anti-tuberculosis (anti-TB) medications (20–22). In the United States 
Public Health Service study published in 1979, the frequency of liver injury due to anti-TB 
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medications was significantly lower in African-American males compared to white males, 
but there existed no such difference among females (20). However, this observation was not 
reproduced in subsequent studies (21,22). In our study, we did not find significant difference 
in the frequency of liver injury due to isoniazid between African-Americans and Caucasians 
(6.2% vs. 3.6%, p=0.16).
The major causes of DILI among African Americans in the DILIN Prospective Study were 
somewhat distinctive. Compared to common causes among Caucasians, the major causes of 
DILI among African-Americans were more likely to be agents that are associated with acute 
and sometimes severe hypersensitivity reactions or those typically present with a “mixed 
hepatocellular-cholestatic” pattern of injury. Thus, TMP/SMZ, phenytoin and allopurinol are 
all associated with immune-allergic type of injury that is commonly “mixed”, and 
methyldopa with an autoimmune phenotype that is commonly hepatocellular. When, 
analyzed by individual agents, African-Americans, who made up 13% of the DILIN cohort, 
represented 27% of TMP/SMZ, 50% of phenytoin, 43% of allopurinol and 55% of 
methyldopa cases. In contrast, African-Americans were underrepresented in the cases of 
amox-clav associated liver injury. Amox-clav has repeatedly been shown to be the most 
common cause of DILI in the western world (2, 10, 23, 24). It is interesting to note that the 
frequency of HLA A*02:01 and HLA DRB1*15:01 alleles which previously have been 
reported as risk factors for liver injury due to amoxicillin-clavulanate is much lower in 
African Americans than in Caucasians (25–27). In one study, the frequency of HLA 
A*02:01 among Caucasians residing in the United States was 27.2% whereas its frequency 
in African Americans was only 12.1% (26). Similarly, the frequency of HLA DRB1*15:01 
in African-Americans was only 3% compared to 25% among Caucasians residing in the 
United States (27). However, the underrepresentation of amoxicillin-clavulanate induced 
liver injury among African-Americans could be due to other factors such as differences in 
underlying infections for which this medication was prescribed, or differences in 
prescription patterns of health care providers.
The liver injury in African-Americans was more severe as reflected by higher DILIN 
severity scores and more frequent hospitalization and was associated with higher frequency 
of worse outcomes such as liver related mortality/liver transplantation and chronic DILI. The 
reasons for this phenomenon are unclear. The duration between earliest DILI symptoms and 
stopping the implicated agent was comparable between the two groups and similarly liver 
biochemistries at DILI presentation were not different between two groups. This suggests 
that greater severity and worse outcomes associated with DILI in African Americans is not 
likely due to a delay in seeking care by African-Americans. Furthermore, except for 
phenytoin, none of the other common causes of DILI in this cohort (TMP/SMX, isoniazid, 
nitrofurantoin, herbal and dietary supplements, or amox-clav) per se were associated with 
more severe liver injury in African-Americans.
The higher frequency of severe cutaneous reactions we observed in African-Americans with 
DILI is intriguing. This does not appear to be differences in the DILI causative agents 
between two groups. Antiepileptic drugs are known to be associated with severe cutaneous 
reactions but the frequency of liver injury due to antiepileptics was not different between 
African-Americans and Caucasians was not different. Trimethoprim/sulfamethoxazole 
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(TMP/SMZ) and allopurinol are known to cause severe cutaneous reactions. Although there 
were more cases of TMP/SMZ and allopurinol associated liver injury among African-
Americans, none were associated with severe cutaneous reactions. It needs to be explored if 
African-Americans have an increased genetic predisposition to severe cutaneous reactions.
In summary, this report summarizes causative agents, clinical aspects and outcomes of well 
characterized DILI in a large cohort of African-Americans. The causative agents, certain 
patterns) and (b) DILI in African Americans may have worse outcomes and thus they may 
be followed closely with intensified follow-up. Further research is needed to better 
understand the basis for these differences. Larger population based studies should be 
conducted to confirm if African-Americans are at increased risk (or lower risk) for liver 
injury from well-recognized hepatotoxic medications. Adequately powered genomic studies 
with optimal control groups should also be conducted to understand if there are genetic 
factors that at least in part explain our observations. clinical features (e.g., frequency of 
severe cutaneous reactions) and outcomes of DILI are distinct in African-Americans. We 
believe that our observations add to the growing body of literature on DILI. It is of value to 
providers to know that (a) some compounds are more likely to cause DILI in AA than in 
Caucasian (may influence their prescription
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1. What is currently known?
• Drug induced liver injury (DILI) is a rare but potentially devastating adverse 
reaction to medications or supplements
• The causes and outcomes of DILI in African-Americans are not well studied.
2. What is new here?
• The most common DILI causative agents differ between African-Americans 
and Caucasians. Trimethoprim/sulfamethoxazole is the most common cause 
for DILI in African-Americans whereas Amoxicillin-clavulanic acid is the 
most common cause for DILI in Caucasians.
• African-Americans are more likely to have severe cutaneous reactions and 
more severe liver injury leading to worse outcomes, including death and liver 
transplant.
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Study Population: Flow Diagram
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Table 1
Demographic and Selected Clinical Features for the African-American and Caucasians with definite, highly 
likely, or probable Drug-Induced Liver Injury
African-Americans (n=144) Caucasians (n=841) P value
Age (years, mean [SD]) 46.9 ± 15.7 50.7 ± 17 0.005
Females (%) 63 57 0.17
High School or Higher Education (%) 83 93 <0.001
Health Insurance (%) 88 95 0.005
BMI (kg/m2, mean [SD]) 29.9 ± 7.6 27.3 ± 6.6 <0.001
Prior drug allergies (%) 38 49 0.02
Alcohol Use (%) 32 55 <0.001
Preexisting Liver Disease (%) 12 9 0.20
Diabetes mellitus (%) 31 22 0.03
Latency (days in median, IQR) 49 (24, 103) 42 (22, 99) 0.60
Days from earliest sign to primary implicated drug stop (days in median, 
IQR)
2 (0.5, 5.5) 3 (0, 12) 0.40
Severe skin reactions (%) 2.1 0.4 0.04
Jaundice (%) 69 69 0.9
Liver Test Results – Onset
ALT (U/L, mean [SD]) 835 ± 893 773 ± 1095 0.10
Alk P (U/L, mean [SD]) 262 ± 199 292 ± 261 0.50
Total bilirubin (mg/dL, mean [SD]) 7.5 ± 7.2 6.4 ± 6.3 0.30
INR 1.4 ± 0.8 1.4 ± 1.0 0.19
Liver Test Results – Peak values
ALT (U/L, mean [SD]) 1117 ± 1126 930 ± 1180 0.01
Alk P (U/L, mean [SD]) 409 ± 383 403 ± 373 0.70
Total bilirubin (mg/dL, mean [SD]) 14.2 ± 11.5 12.7 ± 11.6 0.06
INR 1.9 ± 1.8 1.6 ± 1.5 <0.001
Eosinophilia (>500/μL) (%) 13.4 11.6 0.56
Improvement in liver tests (median days)
Peak ALT to below ULN 66 62 0.40
Peak Alk P to below ULN 142 77 0.06
Peak bilirubin to ≤ 2.5 mg/dL 36 33 0.14
R-ratio (mean, SD) 12 ± 14 12 ± 26 0.14
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African-Americans (n=144) Caucasians (n=841) P value
Pattern of Liver Injury (%)
Hepatocellular 61 51 0.08
Cholestatic 22 25
Mixed 17 24
Abbreviations: ALT, serum alanine aminotransferase; AP, serum alkaline phosphatase; BMI, body mass index; Chol, cholestatic; DILI, drug-
induced liver injury; HC, hepatocellular; INR, international normalized ratio; IQR, interquartile range (25–75%); ULN, upper limit of normal
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Table 2
Implicated Classes and Individual Agents in African-Americans (n=144) and Caucasians (n=841) with 
definite, highly likely, or probable DILI
African-Americans (n=144) Caucasians (n=841)
Top 5 Classes of Implicated Agents 1 Antimicrobials (40%)
2 HDS (14%)
3 Cardiovascular agents (13%)




3 Cardiovascular agents (9%)
4 CNS agents (9%)
5 Anti-neoplastic agents (6%)






7 Unspecified Herbal (3.5%)
8 Allopurinol (2.7%)












HDS: Herbal and dietary supplements; CNS: Central nervous system; Amox-Clav: Amoxicillin and clavulanate; TMP-SMX: Trimethoprim and 
sulfamethoxazole
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Table 3
Causality and Severity Scores and Outcomes of African-American and Caucasians with definite, highly likely, 
or probable Drug-Induced Liver Injury
Feature African-Americans (n=144) Caucasians (n=841) P value
DILIN Causality Score (mean, SD) 2.1 ± 0.7 2.0 ± 0.7 0.08
DILIN Causality (%): Definite 19 25
 Highly likely 53 53 0.20
 Probable 28 23
DILIN Severity Score (mean, SD) 3.0 ± 1.2 2.6 ± 1.2 <0.001
DILIN Severity (%)
Mild 15 23
Moderate 12 24 <0.001
Moderate-Hospitalized 38 29
Severe 24 18
Fatal (within 6 months of onset) 10 6
Hospitalization or non-DILI hospitalization was prolonged (%) 77 56 <0.001
Death, any cause (%) 9.0 5.7 0.10
DILI-related death or Liver Transplantation (%) 10.2 5.8 0.16
Chronicity (%) 24 16 0.06
DILIN: Drug Induced Liver Injury Network; DILI: Drug Induced Liver Injury
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